FDA: Seroquel sales aid is misleading

Share this article:
The FDA has asked AstraZeneca to halt distribution of a professional sales aid used to market its antipsychotic medication Seroquel.

In a warning letter sent to AstraZeneca, the FDA's Division of Drug Marketing, Advertising & Communications (DDMAC) wrote that the sales aid is misleading because it minimizes the risk of side effects associated with Seroquel.

“The promotional material raises significant public health and safety concerns through its minimization of the risks associated with Seroquel,” DDMAC wrote.

AstraZeneca spokesman Jim Minnick told MM&M the company was working closely with the FDA to resolve the matter.

“The purpose of the piece was to convey to healthcare professionals accurate and scientifically substantiated information about the risk of diabetes, accompanied by a copy of the FDA approved product information product labeling,” Minnick said.   

Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.